OBJECTIVES: Mycoplasma genitalium, a sexually transmitted bacterium, faces increasing antibiotic resistance, particularly to azithromycin. However, presence of macrolide resistance-associated mutations (MRAMs) does not evidently implicate azithromycin treatment failure. This study aimed to establish an in vitro co-culture system of M. genitalium isolates and perform phenotypic susceptibility testing for different antibiotics, focusing on azithromycin to evaluate genotypic and phenotypic resistance across MRAMs. METHODS: Urine specimens testing positive for M. genitalium via nucleic acid amplification were co-cultured with Vero cells. Phenotypic susceptibility testing was performed for eight antibiotics. Growth inhibition and MIC of M. genitalium by azithromycin were compared across different MRAMs. RESULTS: M. genitalium was cultured from 20/40 (50.0%) positive urine samples, with phenotypic susceptibility tested in a subset. MICs ranged as follows: azithromycin (0.008->32â mg/L), levofloxacin (1-4â mg/L), moxifloxacin (<0.25-1â mg/L), sitafloxacin (<0.032-0.25â mg/L), minocycline (<0.25-1â mg/L), doxycycline (<0.125-2â mg/L), spectinomycin (<2.5->25â mg/L) and lefamulin (<0.004-0.063â mg/L). Isolates with A2058T demonstrated 24-, 7-, 15- and 12-fold increases in growth inhibition compared with A2058G at azithromycin concentrations of 4, 8, 16 and 32â mg/L, respectively (Pâ<â0.01). MRAMs ranked from low to high impact on MIC range were as follows: wildtype (0.008-0.016), A2058T (8-32), A2059G (â¥32) and A2058G (>32). CONCLUSIONS: This study revealed that M. genitalium isolates vary in azithromycin-induced growth inhibition across MRAMs, potentially explaining differences in clinical treatment efficacy. Phenotypic susceptibility testing for other antibiotics demonstrated relatively low MICs. Future studies should incorporate clinical treatment efficacy and symptom severity to optimize treatment for M. genitalium.
Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations.
阅读:14
作者:Doelman T A, Adriaens N, Westerhuis B M, Bruisten S M, Vergunst C E, Bouwman F M, van Dam A P
| 期刊: | Journal of Antimicrobial Chemotherapy | 影响因子: | 3.600 |
| 时间: | 2025 | 起止号: | 2025 Feb 3; 80(2):465-471 |
| doi: | 10.1093/jac/dkae430 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
